Navigation Links
Drug Shows Dramatic Reduction in Seizures In Patients with Tuberous Sclerosis Complex
Date:7/16/2013

.

The study included 20 patients who were treated with everolimus. Their median age was 8. Half of the patients were enrolled at Cincinnati Children's and half at Texas Children's Hospital in Houston.

The researchers found that everolimus reduced seizure frequency by at least 50 percent in 12 of the 20 participants.  The drug also reduced seizures in 17 of the 20 TSC patients by a median rate of 73 percent. Four patients were free of seizures and seven had at least a 90 percent reduction in seizure frequency.

Overall quality of life, as reported by the participants' parents, also improved.  Parents reported several positive changes, including attention, behavior, social interaction and physical restrictions.

Studies in the 1990s traced the cause of TSC to defects in two genes, TSC1 and TSC2.  When these genes malfunction, the cell has higher activity of mTOR, a protein known to trigger uncontrolled tumor cell and blood vessel growth.  Everolimus shrinks tumors by inhibiting mTORC1, and it appears to reduce seizures in TSC patients in the same way.

"It is unclear whether the benefit of everolimus in treating epilepsy might extend beyond that observed in TSC," says Dr. Krueger.  "mTORC1 has been implicated in genetic and neurodevelopmental syndromes in which epilepsy is prominent and in more common types of epilepsy.  Additional clinical trials might tell us whether everolimus would benefit patients with epilepsy not related to TSC."

Funding for the study was provided by Novartis Pharmaceuticals and the Clack Foundation.

About Cincinnati Children's

Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S.News and World Report's 2013 Best Children's Hospitals ranking. It is ranked #1 for cancer and in the top 10 for nine of 10 pediatric specialties. Cincinnati Children's is one of the top two r
'/>"/>

SOURCE Cincinnati Children's Hospital Medical Center
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
3. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
4. Survey Shows eContent Critical to Corporate Strategies
5. New Forecast Shows Patient Monitoring Systems Market to Reach $18.9 billion by 2016
6. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
7. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
8. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
9. Medical Device Recalls Soar During First Quarter, ExpertRECALL Index Shows
10. New Study Shows Long-Term Effects of Drug Prevention
11. Large-Scale Meta-Analysis Shows Age Not a Social Barrier to Opioid Use and Misuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, ... and development agreements between biotech companies, military ... biotech solutions & therapies with regards to ... to positive clinical enhancements for regenerative medicine ... with recent developments, partnerships and advancements in ...
(Date:8/3/2015)... Biosensors International Group, Ltd. ("Biosensors" or ... B20), a developer, manufacturer and marketer of innovative ... first fiscal quarter ended 30 June 2015 ("Q1 ... Developments: , Biosensors continued to ... driven by lower operating expenses and operational improvement. ...
(Date:8/3/2015)... Colo., Aug. 3, 2015  Array BioPharma Inc. ... the fourth quarter and full year of its ... Ron Squarer, Chief Executive Officer of Array, noted, "Binimetinib ... 3, are on track for regulatory submissions in ... BRAF-mutant melanoma and BRAF-mutant colorectal cancer further validate ...
Breaking Medicine Technology:Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ( www.generex.com ... investor update conference call for late November.  The purpose ... update on (i) the status of the Company,s efforts ... wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), ...
... 24, 2011 Neuralstem, Inc. (NYSE Amex: CUR ... trial of the company,s spinal cord stem cells in the ... at Emory University in Atlanta, Georgia. The company announced that, ... Food and Drug Administration (FDA) has granted approval for the ...
Cached Medicine Technology:Generex Announces Investor Update Conference Call Planned for Late November 2Generex Announces Investor Update Conference Call Planned for Late November 3Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial 2Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial 3Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial 4
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking ... the desire for invasive surgery to achieve this ideal is not. But minimally invasive ... crave without the high cost or lengthy recovery time, according to Valerie Goldburt, ...
(Date:8/4/2015)... St. Louis, MO (PRWEB) , ... August 04, ... ... news, attorneys handling national talcum powder lawsuits filed against Johnson & Johnson report ... documents.* Talcum powder lawyers provide regular news updates and cancer warning ...
(Date:8/4/2015)... ... 2015 , ... Please join us for the 4th Annual Doris A. ... Shores Park in Brewerton, NY. , Doris Connor was a healthy, active, Registered ... age of 59. Her family and friends have since become steadfast in their efforts ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mr Didier Cauchois, ... impressive so far". , Mr Cauchois attributes the success to the dedication ... Dicma and the healthcare technology offered by Winscribe's platform. , "We have ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... partnership to make the Isabel Symptom Checker available to all users of the ... mechanism to check their symptoms in an easy, intuitive method, provides access to ...
Breaking Medicine News(10 mins):Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3
... Eastern Time Today -, IRVINE, Calif., March 13 ... in intravascular patient temperature,management therapies, today reported on its ... year ended December 31, 2007., Revenue for the ... to $2.0 million in the fourth quarter of 2006. ...
... In many areas of the modern world, molecules play ... Taxol is used to combat cancer, and aspirin is ... worldwide. MOLECULES THAT CHANGED THE WORLD (Wiley-Blackwell; March 2008; ... comprehensive guide to not only the synthesis of, but ...
... The following is a,statement by Lois Aronstein, AARP ... including a $400 million Housing,Opportunity Fund to improve the ... be used to provide needed opportunities,for low- and moderate-income ... The program will be administered by the State of ...
... to Expand Brand Awareness with the Strategic Placement, ... Event. Six Members of, this Year,s Field utilize ... RIDGE, N.J., March 13 Millennium,Biotechnologies Inc., wholly-owned ... MBTG) announced today that many PGA,players and spectators ...
... March 13 HHS, Agency for,Healthcare Research and ... health,information technology contracts that will focus on the ... clinical,decision support. Clinical decision support helps health professionals ... Women,s Hospital in Boston and Yale University School,of ...
... showed significant improvement in social functioning , , THURSDAY, ... 30 minutes of exercise a day can improve the ... American researchers suggest. , The analysis studied hundreds ... the Dose Response to Exercise in postmenopausal Women (DREW) ...
Cached Medicine News:Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 2Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 3Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 4Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 5Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 6Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 7Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 8Health News:Molecules that changed the world 2Health News:SURGEX(TM) Joins the Team of Sponsors for the PGA Tour's 2008 Arnold Palmer Invitational Presented by MasterCard 2Health News:SURGEX(TM) Joins the Team of Sponsors for the PGA Tour's 2008 Arnold Palmer Invitational Presented by MasterCard 3Health News:SURGEX(TM) Joins the Team of Sponsors for the PGA Tour's 2008 Arnold Palmer Invitational Presented by MasterCard 4Health News:AHRQ Awards $5 Million to Help Integrate Clinical Decision Support Technologies Into Health Care Delivery 2Health News:Minimal Exercise Benefits Overweight Postmenopausal Women 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: